Patents Examined by Yan Xiao
  • Patent number: 11439620
    Abstract: The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Thomas M. Cardillo
  • Patent number: 11413282
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 16, 2022
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • Patent number: 11401506
    Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 2, 2022
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board nf Regents The Inivercitvof Texas Cvctom
    Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
  • Patent number: 11397184
    Abstract: Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 26, 2022
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventor: Peter Ordentlich
  • Patent number: 11382985
    Abstract: The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mAb) therapy. Such vaccines cur mAbs may be used in the treatment of cancer.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 12, 2022
    Assignee: Scancell Limited
    Inventors: Linda Gillian Durrant, Victoria Anne Brentville, Rachel Louise Metheringham
  • Patent number: 11376269
    Abstract: The present invention relates to pharmaceutical compositions for use in the treatment of chemoresistant acute myeloid leukemia (AML). The inventors have established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease as observed in AML patients after chemotherapy. The inventors showed that cytarabine-resistance mechanism involves the CD39-dependent crosstalk between energetic niche and AML mitochondrial functions through CD39-P2Y13-cAMP-PKA signaling axis. In particular, the present invention relates to an inhibitor of the CD39-P2Y13-cAMP-PKA signaling axis for use in a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of said inhibitor.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: July 5, 2022
    Assignees: INSERM, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Jean-Emmanuel Sarry, Christian Recher, Fabienne De Toni-Costes, Nesrine Aroua
  • Patent number: 11377495
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: July 5, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman, Siddhartha Jaiswal, Mark P. Chao
  • Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • Patent number: 11376255
    Abstract: The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-?-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers. The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: July 5, 2022
    Assignee: iTeos Belgium SA
    Inventors: Stefano Crosignani, Erica Joke Katelijne Heleen Houthuys, Reece Gerrad Marillier, Chiara Martinoli, Oliver De Henau, Gregory Driessens
  • Patent number: 11370838
    Abstract: The invention provides improved methods of conjugating an agent to a thiol moiety in a protein that contains at least one disulfide bond and at least one trisulfide bond. Exemplary embodiments include the production of antibody drug conjugates substantially free of impurities created in the presence of reactive sulfide moieties in the production processes.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: June 28, 2022
    Assignee: GENENTECH, INC.
    Inventors: Jayme Franklin, Xin Xin Lin, Jeffrey Gorrell, Timothy Tully, Matthew Hutchinson, Charity Tucker Bechtel
  • Patent number: 11369687
    Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 28, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 11365258
    Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: June 21, 2022
    Assignee: BERLIN-CHEMIE AG
    Inventors: Monica Binaschi, Mario Bigioni, Giuseppe Merlino, Cecilia Simonelli, Francesco Bertoni, Andrea Pellacani
  • Patent number: 11365230
    Abstract: This patent application relates generally to the treatment of cancer, and more particularly to the use of a pseudotyped lentivirus expressing IL-12 for the treatment of cancer.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: June 21, 2022
    Assignee: IMMUNE DESIGN CORP.
    Inventors: Jan Henrik Ter Meulen, Peter Lars Aksel Berglund, Tinglan Tina Albershardt
  • Patent number: 11357796
    Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 14, 2022
    Assignee: KITE PHARMA, INC.
    Inventors: John M. Rossi, Adrian I. Bot
  • Patent number: 11353459
    Abstract: Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 7, 2022
    Assignee: CREATV MICROTECH, INC.
    Inventors: Daniel Adams, Cha-Mei Tang
  • Patent number: 11351235
    Abstract: Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: June 7, 2022
    Inventor: Michael G. Hanna, Jr.
  • Patent number: 11338028
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen are disclosed. Methods of treating a subject with a LEMD1-expressing tumor and methods of preventing a LEMD1-expressing tumor are disclosed. Mutated consensus LEMD1 antigen is disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Patent number: 11340229
    Abstract: Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 24, 2022
    Assignees: Abbott Japan LLC, The University of Tokyo
    Inventors: Toru Yoshimura, Eisaku Yoshida, Naohiko Koshikawa, Motoharu Seiki
  • Patent number: 11339201
    Abstract: The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 24, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Sarah C. Garrett-Thomson, Steven C. Almo, Ronald D. Seidel, III
  • Patent number: 11338026
    Abstract: Described herein are methods of identifying immunologically protective neo-epitopes from the cancer tissue DNA of cancer patients using biophysical principles as well as bioinformatics techniques. The identification of immunologically protective neo-epitopes provides pharmaceutical compositions with a limited number of tumor-specific peptides suitable for personalized genomics-driven immunotherapy of human cancer. Specifically disclosed herein is a method of using the conformational stability of an epitope in an MHC protein-binding groove to predict immunogenicity of peptides in a putative neo-peptide set from a tumor from a cancer patient. Pharmaceutical compositions and methods of administration are also included.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: May 24, 2022
    Assignees: THE UNIVERSITY OF CONNECTICUT, UNIVERSITY OF NOTRE DAME DUE LAC
    Inventors: Pramod K. Srivastava, Brian M. Baker